Journal of Medical Economics Article Demonstrates Economic Benefits of Cardiovascular Systems Orbital Atherectomy in the Treatment of Peripheral Artery Disease

HRS Scientific Sessions: Boston Scientific LBCT

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

What are the Most Commonly Performed Surgeries?

Whether you are trying to learn more about a surgery you are planning to have or find out what the most common procedures are, this list is here for you. Read more.

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

Cardiovascular Systems, a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that a new article published in the Journal of Medical Economicsreviews the two-year PAD-related health care costs of patients enrolled in the LIBERTY 360° trial.

LIBERTY 360° represents the largest, contemporary real-world experience with various endovascular strategies across the full range of Rutherford Class (RC) patients, including those with critical limb ischemia, the most compromised RC6 patients.

In the article, “Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: results from the LIBERTY 360° trial” by Elizabeth A. Magnuson, et al., the authors note that among patients with symptomatic lower extremity PAD undergoing endovascular revascularization, initial treatment costs and total 2-year costs varied significantly according to clinical and lesion-level characteristics, as well as symptom burden.

Said Scott Ward, CSI’s Chairman, President and Chief Executive Officer, “Data from the LIBERTY 360° study revealed high freedom from major amputation out to three years (RC2-3, 98.5%; RC4-5, 94.0%; and RC6, 79.9%). And the orbital atherectomy sub analysis of this data indicated high freedom from major amputation (RC2-3, 100%; RC4-5, 95.3%; and RC6, 88.6%) with no additional amputations reported after the two-year visit. These data are especially compelling in the context of cost analyses showing that the durable patient outcomes from the use of orbital atherectomy resulted in lower mean cumulative PAD-related costs one- and two-years after the procedure.”

LIBERTY 360° (OAS RC2-6) 2-Year Costs

Orbital atherectomy (RC2-6; N=503) mean index procedure cost was $11,729 and by two-years the mean costs were $29,474, numerically lower than the overall LIBERTY (RC2-6; N=1189) mean two-year cost of $30,491.

PAD-related costs ($) up to 2 years following the index procedure

All Patients

Any Orbital

All Patients

Any Orbital

Index Hospitalization


(11,189 to 12,081)


(11,165 to 12,443)

Years 1+2 follow-up


(17,046 to 20,802)


(15,113 to 20,835)

Year 1 follow-up


(10,597 to 12,974)


(9,344 to 12,741)

Endovascular procedures


(6,730 to 8,263)


(5,758 to 8,127)

Endovascular procedures


(10,321 to 12,688)


8,944 to 12,916)

Surgical procedures


1,218 to 2,041)


(1,096 to 2,384)

Surgical procedures


(1,616 to 2,569)


(1,353 to 2,708)

Other PAD hospitalizations


(74 to 211)


(34 to 231)

Other PAD hospitalizations


(113 to 278)


(41 to 251)

Outpatient/ chronic care


(2,011 to 3,000)


(1,586 to 3,126)

Outpatient/ chronic care


(4,041 to 6,253)


(3,272 to 6,791)

Cumulative 1-year


(22,110 to 24,623)


(20,998 to 24,627)

Cumulative 2-year


(28,569 to 32,506)


(26,655 to 32,665)

Magnuson EA, et al. J Med Econ. 2021 April 18:1



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.